Frontiers in Molecular Biosciences · Nov 10, 2026

Molecular Basis of IGF1 as a Double-Edged Sword in Longevity and Cancer

By Li Xiao, Jianhua Li, Dong Weixia et al.

Insulin-like growth factor 1 (IGF1) is a peptide growth factor central to the regulation of growth, metabolism, cell proliferation, and apoptosis. The IGF1 signaling pathway exerts opposing effects on lifespan and tumorigenesis: moderate inhibition extends lifespan and healthspan across model organisms, whereas excessive activation of the IGF1R axis—most often driven by IGF2/IR-A and IGF1R/IR hybrid receptors in solid tumors—promotes survival, proliferation, and tumorigenesis through PI3K/Akt/mTOR and RAS/RAF/MAPK. Importantly, the pro-tumorigenic effect attributed to 'IGF1 signaling' must be interpreted with caution: in many solid tumors the predominantly overexpressed ligand is IGF2 rather than IGF1, and oncogenic output is largely mediated through the IGF1R receptor axis, including IGF2/IR-A and IGF1R/IR hybrid receptors. The 'double-edged sword' is therefore best understood as an emergent, network-level property—determined jointly by ligand identity (IGF1 vs IGF2), receptor combination (IGF1R homodimers, IGF1R/IR hybrids, and IR-A), and tissue context—rather than as an intrinsic property of the IGF1 ligand alone. This ligand–receptor stratification partly explains the clinical limitations of IGF1R-selective agents.

The paperJournal siteMechanisms

AgingResearch.News